UNSPSC 51434205: Reserpine

This classification denotes a multidrug resistance modulator and adrenergic agent with the molecular formula C33H40N2O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8B1QWR724A, chemically known as 20alpha-yohimban-16beta-carboxylic acid, 18beta-hydroxy-11,17alpha-dimethoxy-, methyl ester, 3,4,5-trimethoxybenzoate (ester) (8ci) but generally known as reserpine, which bears US NIH Compound Identifier 5052.

UNSPSC 51434205 Reserpine is a Commodity code covering pharmaceutical active ingredients and finished medications supplied to state and local emergency services, healthcare systems, and human services agencies. State and local procurement under this code spans both emergency life support drugs and broader pharmaceutical supply agreements. The City of Tampa's Fire Rescue procurement exemplifies the narrower scope—sealed bids for specific advanced life support medications including Labetalol, Epinephrine, Adenosine, and Diltiazem vials for immediate operational use. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP represents the broader application, soliciting generic multi-source pharmaceuticals and over-the-counter products for distribution across participating state and local government facilities. Issuing bodies include city procurement departments (Tampa), state human services commissions (Texas HHS Commission), and cooperative purchasing consortia (MMCAP). The Texas HHS RFI signals emerging interest in direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels, though that solicitation remains exploratory and does not commit funding or timeline.

Geographic activity centers on Texas, Minnesota, and Florida based on recent opportunities. The City of Tampa (Hillsborough County, Florida) issued an IFB for Advanced Life Support Medications (26P00188) with a due date of April 8, 2026, and an estimated contract value of $40,000.00; the contract runs one year with options to renew for two additional one-year periods, and the procurement carries a Small Local Business Enterprise (SLBE) sheltered market designation with a 5 percent bid discount not to exceed $10,000. MMCAP's RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, spans multiple states including Minnesota and Oregon; evaluated vendors will supply through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson) with a contract term of two years and performance penalties ranging from $200 to $1,500 per violation. The Texas HHS Commission's RFI (HHS0017013, due April 3, 2026) is information-gathering only and does not reflect committed procurement activity at this stage.